Neurocrine Biosciences annual debt-to-ebitda ratio
2018
2019
2020
2021
2022
2023
2024
2025
Neurocrine Biosciences Debt-to-EBITDA Ratio Growth & History (NBIX)
Neurocrine Biosciences's debt-to-ebitda ratio was 0.73 for fiscal 2025.
View full Neurocrine Biosciences company overviewNeurocrine Biosciences annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.73 | −0.10 | −12.48% |
| 2024 | 2024-12-31 | 0.83 | −0.24 | −22.22% |
| 2023 | 2023-12-31 | 1.07 | 0.65 | +154.46% |
| 2022 | 2022-12-31 | 0.42 | −3.61 | −89.60% |
| 2021 | 2021-12-31 | 4.03 | 1.57 | +63.60% |
| 2020 | 2020-12-31 | 2.46 | −3.86 | −61.04% |
| 2019 | 2019-12-31 | 6.32 | −3.19 | −33.57% |
| 2018 | 2018-12-31 | 9.52 | — | — |
Neurocrine Biosciences quarterly debt-to-ebitda ratio
Q3.18
Q4.18
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.55 | −0.39 | −41.41% |
| Q1 2026 | 2026-03-31 | 0.57 | −0.38 | −39.92% |
| Q4 2025 | 2025-12-31 | 0.73 | −0.10 | −12.48% |
| Q3 2025 | 2025-09-30 | 0.83 | 0.35 | +74.72% |
| Q2 2025 | 2025-06-30 | 0.94 | 0.42 | +79.97% |
| Q1 2025 | 2025-03-31 | 0.94 | 0.35 | +59.36% |
| Q4 2024 | 2024-12-31 | 0.83 | −0.24 | −22.22% |
| Q3 2024 | 2024-09-30 | 0.47 | 0.01 | +2.27% |
| Q2 2024 | 2024-06-30 | 0.52 | −0.11 | −17.69% |
| Q1 2024 | 2024-03-31 | 0.59 | −1.27 | −68.25% |
| Q4 2023 | 2023-12-31 | 1.07 | 0.65 | +154.46% |
| Q3 2023 | 2023-09-30 | 0.46 | −0.46 | −49.80% |
| Q2 2023 | 2023-06-30 | 0.63 | −2.98 | −82.54% |
| Q1 2023 | 2023-03-31 | 1.86 | −3.93 | −67.85% |
| Q4 2022 | 2022-12-31 | 0.42 | −3.61 | −89.60% |
| Q3 2022 | 2022-09-30 | 0.92 | −1.13 | −55.03% |
| Q2 2022 | 2022-06-30 | 3.62 | 0.19 | +5.45% |
| Q1 2022 | 2022-03-31 | 5.79 | 2.74 | +89.67% |
| Q4 2021 | 2021-12-31 | 4.03 | 1.57 | +63.60% |
| Q3 2021 | 2021-09-30 | 2.05 | −1.44 | −41.20% |
| Q2 2021 | 2021-06-30 | 3.43 | 1.61 | +88.96% |
| Q1 2021 | 2021-03-31 | 3.05 | 0.94 | +44.25% |
| Q4 2020 | 2020-12-31 | 2.46 | −3.86 | −61.04% |
| Q3 2020 | 2020-09-30 | 3.49 | −5.88 | −62.76% |
| Q2 2020 | 2020-06-30 | 1.81 | −28.99 | −94.11% |
| Q1 2020 | 2020-03-31 | 2.12 | — | — |
| Q4 2019 | 2019-12-31 | 6.32 | −3.19 | −33.57% |
| Q3 2019 | 2019-09-30 | 9.37 | 9.37 | — |
| Q2 2019 | 2019-06-30 | 30.80 | — | — |
| Q4 2018 | 2018-12-31 | 9.52 | — | — |
| Q3 2018 | 2018-09-30 | 0.00 | — | — |
Neurocrine Biosciences debt-to-ebitda ratio trends
Over the last five fiscal years, Neurocrine Biosciences's debt-to-ebitda ratio decreased from 2.46 to 0.73, a change of −1.74. The latest reported quarter, Q2 2026, shows 0.55.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Neurocrine Biosciences source filings ↗